<DOC>
	<DOCNO>NCT00432796</DOCNO>
	<brief_summary>The purpose study determine effectiveness safety LMWH postoperative bridging therapy ( standard care ) versus postoperative placebo bridge therapy ( experimental arm ) patient mechanical heart valves atrial fibrillation atrial flutter high risk stroke warfarin temporarily interrupt procedure .</brief_summary>
	<brief_title>PERIOP 2 - A Safety Effectiveness LMWH v Placebo Bridging Therapy Patients Long Term Warfarin Requiring Temporary Interruption Warfarin .</brief_title>
	<detailed_description>There grow number patient receive long-term warfarin therapy prevention arterial thromboembolism . The current approach perioperative management anticoagulation ( i.e . `` bridge therapy '' ) low molecular weight heparin ( LMWH ) standardize assessed adequate randomize study . Most clinician , however , recommend bridge therapy . We recently complete multicentre single arm pilot study LMWH bridging therapy . This study 10 centre accrue 224 patient 10 month . In pilot study postoperative thromboembolic event rate 3.1 % 75 % occur patient anticoagulation hold due bleeding . Design : A prospective multicentre randomize double-blind control trial . Patients : Consecutive eligible consent patient 11 teach hospital Canada . A total 1773 patient prosthetic heart valve receive long-term oral anticoagulation warfarin patient atrial fibrillation/flutter major risk factor require elective non-cardiac surgery invasive procedure necessitate reversal oral anticoagulant therapy . Treatment Schedule : Consent obtain preoperatively randomization perform postoperatively confirm eligibility . Preoperative period : In participant , warfarin therapy discontinue five day prior procedure . Dalteparin , LMWH , administer 200 IU/kg sc early morning three day prior , include day , procedure except day prior surgery dose 100 I.U./kg give 24 hour preoperatively . Warfarin resume evening procedure . Postoperative period : Dalteparin placebo administer daily ( start morning procedure ) , provide surgical hemostasis achieve , continue least four day INR &gt; 2.0 . Patients consider high risk postoperative major bleed give dalteparin placebo dose 5,000 IU sc daily . Patients undergo procedure consider low risk bleed complication resume dalteparin placebo 200 IU/Kg s.c. daily . Outcomes : The primary outcome frequency episodes major thromboembolism 90-day follow-up period follow time randomization . Secondary outcome include major bleed overall survival . Relevance : To bridge bridge , common clinical question , without randomize trial evidence guide clinician . This RCT answer whether post-operative bridging reduces risk thromboembolism cause harm .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . Informed consent , 2 . Patients age &gt; 18 3 . Patients prosthetic ( mechanical ) heart valve 4 . Patients atrial fibrillation atrial flutter major risk factor ( previous TIA stroke , high blood pressure , diabetes , age &gt; 75 , moderate/severe leave ventricle dysfunction ) 5. Who receive longterm oral anticoagulation require elective noncardiac surgery invasive procedure reversal anticoagulant therapy . 1 . Evidence active bleeding within last 30 day prior stop warfarin . 2 . Platelet count &lt; 100 x 109/L . 3 . Spinal neurosurgery . 4 . Life expectancy le 3 month . 5 . Calculated creatinine clearance &lt; 30 ml/min 6 . Patients require cardiac surgery . 7 . Multiple prosthetic ( mechanical ) valve StarrEdwards valve prosthetic ( mechanical ) valve history stroke TIA 8 . History heparin induce thrombocytopenia ( HIT )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Anticoagulation</keyword>
	<keyword>Prosthetic heart valve</keyword>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Bridging Therapy</keyword>
	<keyword>Thromboembolism</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Low Molecular Weight Heparin</keyword>
</DOC>